- The Hoge Raad (Supreme Court) ruled that Bravecto Spot-On Cat and Bravecto Spot-On Dog cannot be classified as medicinal products under heading 3004 of the Combined Nomenclature (CN), despite their intended use for flea control and prevention.
- The dispute arose from customs declarations submitted by X BV, which claimed the products were medicinal and subject to a 0% rate, while the inspector classified them as insecticides, applicable to a 6% rate, leading to a demand for customs duties payment.
- The Supreme Court concluded that the products’ insecticidal and acaricidal effects do not meet the criteria for classification as medicinal products, as they lack specific therapeutic properties, and upheld the lower court’s factual findings that the products do not have curative or preventive effects targeting specific animal functions.
Source Taxlive
Latest Posts in "Netherlands"
- Amendments to VAT Compensation Fund Scheme for Investment Services Effective April 2026
- Court Rejects Proposed Settlement in VAT Fraud Case Due to Evidence and Sentence Concerns
- Dutch Tax Administration Update: Emergency VAT E-commerce Track Extended to 2028, Digital Mail Option in 2025
- Amendment to VAT Compensation Fund Rules for Investment Services Effective April 2026
- ViDA E‑Invoicing and Digital Reporting in the Netherlands: Strategic Choices and Phased Timeline to 2032
